PDF(Pubmed)
Abstract：
Following the introduction of RNA-based vaccines, COVID-19 vaccine-associated clinical lymphadenopathy (C19-LAP) has been reported as a side effect. Moreover, subclinical lymphadenopathy detected on imaging (SLDI) has also been observed, mainly as incidental findings while performing screening tests on oncological patients. In these cases, surgical lymphadenectomy, fine-needle aspiration cytology (FNAC) and core needle biopsy (CNB) have been used as a valuable diagnostic tool for SLDI and C19-LAP. In this review the clinical, histologic and cytologic features of SLDI and C19-LAP have been investigated. A search for studies that reported on C19-LAP and SLDI histopathology and cytopathology was performed on PubMed and Google Scholar, on 11 January 2023. Thirty-one reports on SLDI and C19-LAP were retrieved and included in a pooled analysis. In total, we included 54 patients with a median age of 47 years. In our research, surgical excision, CNB and/or FNAC of C19-LAP or SLDI enlarged lymph nodes have been performed in 54 cases. Of all cases, only two metastases were diagnosed and one case was diagnosed as reactive hyperplasia with atypical follicles. The remaining cases were reactive lymphadenopathy (28 cases), follicular hyperplasia (13 cases), Kikuchi-Fujimoto disease (6 cases), granulomatous lymphadenitis (2 cases), eosinophilic lymph node abscesses (1 case), Langherans cell histiocytosis (1 case), Rosai-Dorfman disease (1 case). SLDI and C19-LAP have represented a diagnostic dilemma, especially in oncologic patients. The role of different diagnostic tools for SLDI and C19-LAP has been discussed.
摘要：
在引入基于RNA的疫苗之后，据报道，COVID-19疫苗相关的临床淋巴结病(C19-LAP)是一种副作用。此外，还观察到成像检测到的亚临床淋巴结病（SLDI），主要作为对肿瘤患者进行筛查测试时的偶然发现。在这些情况下,手术淋巴结清扫术,细针穿刺细胞学(FNAC)和芯针活检(CNB)已被用作SLDI和C19-LAP的有价值的诊断工具。在这篇综述中，研究了SLDI和C19-LAP的组织学和细胞学特征。在PubMed和GoogleScholar上进行了对C19-LAP和SLDI组织病理学和细胞病理学报道的研究的搜索，2023年1月11日检索了31份有关SLDI和C19-LAP的报告，并将其纳入汇总分析。总的来说,我们纳入了54例患者,中位年龄为47岁.在我们的研究中,手术切除,已对54例C19-LAP或SLDI肿大淋巴结进行了CNB和/或FNAC。在所有案件中，仅诊断出2例转移瘤，1例诊断为反应性增生伴不典型卵泡。其余均为反应性淋巴结肿大（28例），卵泡增生（13例），Kikuchi-Fujimoto病（6例），肉芽肿性淋巴结炎（2例），嗜酸性淋巴结脓肿（1例），兰氏细胞组织细胞增生症（1例），Rosai-Dorfman病（1例）。SLDI和C19-LAP代表了诊断困境，尤其是肿瘤患者。已经讨论了SLDI和C19-LAP的不同诊断工具的作用。
